TransMedics Group (TMDX) Stock Forecast & Price Target

$123.84 -0.87 (-0.70%)

As of 10:08 AM Eastern

TransMedics Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
3

Buy
8

Based on 11 Wall Street analysts who have issued ratings for TransMedics Group in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 3 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for TMDX.

Consensus Price Target

$126.70
2.31% Upside

According to the 11 analysts' twelve-month price targets for TransMedics Group, the average price target is $126.70. The highest price target for TMDX is $178.00, while the lowest price target for TMDX is $75.00. The average price target represents a forecasted upside of 2.31% from the current price of $123.84.

Get the Latest News and Ratings for TMDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for TransMedics Group and its competitors.

TMDX Analyst Ratings Over Time

Type	Current Forecast 5/21/24 to 5/21/25	1 Month Ago 4/21/24 to 4/21/25	3 Months Ago 2/21/24 to 2/20/25	1 Year Ago 5/22/23 to 5/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$126.70	$122.70	$122.70	$119.00
Forecasted Upside	2.31% Upside	39.88% Upside	62.62% Upside	-14.03% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

TMDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TMDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

TransMedics Group Stock vs. The Competition

Type	TransMedics Group	Medical Companies	S&P 500
Consensus Rating Score	2.82	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.60% Upside	4,843.17% Upside	13.03% Upside
News Sentiment Rating	Positive News See Recent TMDX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/9/2025	Oppenheimer 3 of 5 stars	Suraj Kalia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$125.00 ➝ $130.00	+13.57%
5/9/2025	Piper Sandler 2 of 5 stars	Matt O'Brien Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $125.00	+9.41%
4/23/2025	Needham & Company LLC 2 of 5 stars	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/11/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00 ➝ $104.00	+53.99%
12/17/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral	$116.00 ➝ $75.00	+16.79%
12/11/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$150.00 ➝ $120.00	+73.94%
11/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$175.00 ➝ $120.00	+48.64%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/2/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Sellers Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$151.00 ➝ $178.00	+18.98%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$104.00 ➝ $145.00	+0.58%
Get the Latest News and Ratings for TMDX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.
6/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$161.00	+21.03%
7/19/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Daniels Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:08 AM ET.

Should I Buy TransMedics Group Stock? TMDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, May 8, 2025. Please send any questions or comments about these TransMedics Group pros and cons to contact@marketbeat.com.

TransMedics Group
Bull Case

Here are some ways that investors could benefit from investing in TransMedics Group, Inc.:

The stock price recently increased by 2.7%, reaching $95.89, indicating positive market sentiment and potential for further growth.
TransMedics Group, Inc. has a strong institutional backing, with 99.67% of its stock owned by institutional investors and hedge funds, suggesting confidence in the company's future.
Analysts have a consensus rating of "Moderate Buy" with an average price target of $124.20, indicating potential upside for investors based on current valuations.
Recent upgrades from analysts, including Piper Sandler raising its price objective to $105.00, reflect growing confidence in the company's performance and prospects.
The company has demonstrated strong financial metrics, including a current ratio of 8.20, which indicates good short-term financial health and ability to cover liabilities.

TransMedics Group
Bear Case

Investors should be bearish about investing in TransMedics Group, Inc. for these reasons:

The company has a high price-to-earnings (P/E) ratio of 102.01, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
TransMedics Group, Inc. has a debt-to-equity ratio of 2.42, indicating a higher level of debt compared to equity, which could pose risks if the company faces financial challenges.
Despite recent positive movements, the stock has a significant 1-year high of $177.37, suggesting volatility and the potential for substantial losses if the stock price declines.
Market conditions can be unpredictable, and the healthcare sector can be particularly sensitive to regulatory changes, which may impact the company's operations and stock performance.
With a beta of 1.91, the stock is more volatile than the market, meaning it could experience larger price swings, which may not be suitable for all investors.

TMDX Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for TransMedics Group is $126.70, with a high forecast of $178.00 and a low forecast of $75.00.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 3 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMDX shares.
: According to analysts, TransMedics Group's stock has a predicted upside of 2.31% based on their 12-month stock forecasts.
: TransMedics Group has been rated by research analysts at Canaccord Genuity Group, Needham & Company LLC, Oppenheimer, and Piper Sandler in the past 90 days.
: Analysts like TransMedics Group more than other "medical" companies. The consensus rating score for TransMedics Group is 2.82 while the average consensus rating score for "medical" companies is 2.81. Learn more on how TMDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:TMDX) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Stock Forecast & Price Target